The purpose of Фотил is to provide long-term therapeutic support for chronic eye conditions where the primary risk factor is elevated fluid pressure. This combination is commonly used when additional symptomatic support is appropriate for managing pressure.

Management of Chronic Open-Angle Glaucoma

This medication is commonly used across conditions presenting with systemic or localized discomfort related to persistently high intraocular pressure (IOP), such as Primary Open-Angle Glaucoma and Ocular Hypertension. The combined use is generally considered relevant when supportive symptom management of this key risk factor is appropriate. This therapeutic support may assist with addressing the pressure buildup, contributing to the management of the chronic condition.

Sustained Control to Preserve Visual Function

This therapeutic approach contributes to easing the overall symptom load related to the risk of visual function loss. By achieving a sustained and significant reduction in high eye pressure, Фотил supports the patient during difficult episodes by easing distress related to optic nerve damage risk. This approach may be part of symptomatic management relevant for addressing the risk of progression and supporting functional stability.

Intervention for Inadequately Controlled Eye Pressure

The combination is applied in clinical settings that involve unstable symptom patterns where additional symptomatic support is needed, addressing a symptom cluster that may become intense or disruptive to the optic nerve. The combination is relevant in contexts involving heightened systemic burden where additional symptomatic support is appropriate for managing pressure, which may assist with maintaining functional stability for the patient.

---

Quick Fact: Relief for Elevated Eye Pressure

Property	Description
Primary Risk Factor Addressed	Pathologic Intraocular Pressure (IOP) Elevation
Key Therapeutic Goal	Sustained support for maintaining target pressure
Typical Use Context	When single-agent therapy is inadequate

Regulatory References

1. Health Canada Product Monograph for TIMPILO®

Eligibility Scope

Field	Status
Populations for whom use is allowed	Adult patients (typically 18 years and older) who require sustained Intraocular Pressure (IOP) reduction for chronic open-angle glaucoma or ocular hypertension.
Populations for whom use is not recommended	Pregnant women unless deemed clearly necessary; Nursing mothers must make a decision to discontinue the drug or discontinue nursing.
Populations for whom use is contraindicated	Patients with bronchial asthma or a history of the condition; severe Chronic Obstructive Pulmonary Disease (COPD); severe cardiac disorders, including sinus bradycardia, second or third degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock.

---

Age- and Condition-Specific Rules

Classification	Status
Age-related Eligibility	Safety and effectiveness are not established in children younger than 2 years of age. No specific dosage adjustment is noted for older adult (geriatric) patients.
Eligibility-related Restrictions	Use requires caution in patients with conditions like diabetes mellitus or spontaneous hypoglycemia, as the medicine may mask symptoms. Caution is also advised for those with First Degree AV Block, cerebrovascular insufficiency, or Myasthenia Gravis.

---

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use this combination medicine primarily through a list of absolute contraindications related to severe respiratory and cardiac diseases, driven by the systemic absorption of the Timolol component. Eligibility for other populations is determined by specific warnings requiring caution or is limited by the classification of use not established in young children.

Interactions with other medicines and products

The active components of Фотил, particularly the Timolol component, can be systemically absorbed and may interact with co-administered medicinal products, which is detailed in regulatory labeling. These documented interactions fall into two main official categories: those causing additive systemic effects and those altering Timolol's concentration in the body.

---

Pharmacodynamic Interactions and Additive Effects

The co-administration of Фотил with agents that slow heart rate or lower blood pressure may lead to additive systemic effects. The use of Фотил with oral or topical beta-adrenergic blocking agents is officially not recommended due to the risk of excessive systemic beta-blockade. Caution is also warranted with Calcium Antagonists (oral or intravenous), which may contribute to atrioventricular conduction disturbances, and with catecholamine-depleting drugs (e.g., reserpine), which may result in marked bradycardia and hypotension. The co-use of Фотил alongside Digitalis may prolong atrioventricular conduction time.

---

Metabolic and Timing Constraints

The systemic exposure to Timolol is officially reported to increase when co-administered with potent CYP2D6 inhibitors (such as quinidine and certain SSRIs). This is a pharmacokinetic interaction that can enhance systemic beta-blockade. Furthermore, a procedural constraint applies to co-administration with any other topical ophthalmic drugs: these medicines must be administered at least five minutes apart from Фотил to ensure proper absorption.

How Фотил Works

The action of Фотил is defined by two complementary mechanisms that influence the dynamics of aqueous humor, specifically its formation (inflow) and its physical exit (outflow).

---

Enhancing Ocular Fluid Outflow via Cholinergic Agonism

This domain covers the action of Pilocarpine, which works by directly activating the M3 muscarinic receptors on the ciliary body muscle. This stimulation causes the muscle to contract, which mechanically pulls on the trabecular meshwork structure. This physical action reduces outflow resistance, which facilitates the exit rate of aqueous humor from the eye.

---

Inhibiting Aqueous Humor Inflow via Beta-Blockade

The second domain involves Timolol, which functions as a non-selective antagonist on beta-adrenergic receptors (beta1 and beta2) in the ciliary epithelium. By blocking the sympathetic nervous system's signaling, this mechanism inhibits the active secretion process and ultrafiltration, reducing the rate of new aqueous humor formation.

---

Complementary Effect on Intraocular Pressure (IOP)

The simultaneous action of increasing outflow and decreasing inflow alters the ocular fluid volume dynamics. This results in the primary physiological consequence of the mechanism: a reduction in Intraocular Pressure.

How to Use Фотил

Фотил (Pilocarpine/Timolol fixed-dose solution) is administered exclusively via topical ocular administration, meaning it is applied directly as eye drops into the conjunctival sac of the affected eye(s). The medication is designed for long-term therapeutic support in chronic eye conditions.

---

Standard Dosing and Frequency

The standard regimen requires instillation of one drop of the ophthalmic solution per application, administered twice daily. This schedule typically involves morning and evening dosing for sustained action. The combination is generally used when prior single-agent therapy (such as a beta-blocker or pilocarpine alone) has been insufficient for achieving the target reduction in intraocular pressure.

Usage Constraint	Instruction
Dose per Application	One drop
Frequency	Twice daily
Missed Dose Rule	If a dose is forgotten, the patient should skip the missed dose and resume the regular schedule. A double dose must not be used to compensate.

---

Administration Technique and Constraints

Proper technique is crucial for adherence and efficacy. Immediately after instilling the drop, the patient should gently close the eye and apply light pressure to the nasolacrimal duct (at the inner corner of the eye) for approximately two minutes. This measure is used to limit the amount of the drug absorbed systemically.

If other topical eye medications are required, they must be administered at least 10 minutes before or after the use of Фотил. Furthermore, any soft contact lenses must be removed before application and should not be reinserted until 15 minutes have passed. The safety and effectiveness of this specific fixed-dose combination in children have not been established.

Research evidence / Overview of studies for Фотил

Evidence for Use in Primary Open-Angle Glaucoma

The research investigating the pilocarpine/timolol fixed combination (Фотил) centers largely on studies in chronic Primary Open-Angle Glaucoma. The primary evidence base consists of Randomized Controlled Trials (RCTs) and other controlled clinical trials. These study designs were used to compare the fixed combination against its individual components or the two components used separately, focusing on adult patients whose high eye pressure (IOP) remained elevated despite using a single topical medication alone.

Research examined the effect on the IOP biomarker, tracking both the mean pressure measurement and how the eye pressure was measured throughout the day. Studies observed patterns that findings described how the fixed combination showed a different measurement pattern for the IOP biomarker compared to its individual active components administered alone. Follow-up durations were typically limited, lasting up to 48 weeks (one year).

Evidence for Use in Ocular Hypertension

Фотил was also evaluated in adult populations diagnosed with Ocular Hypertension. This evidence concerns a condition marked by persistently elevated eye pressure, which was the focus of studies without reference to existing optic nerve damage. Research focused heavily on measuring the mean change in the IOP biomarker from baseline and the ability to maintain the pressure below a target threshold.

Understanding the Study Landscape and Research Gaps

What remains uncertain is the long-term outcome of this specific fixed combination on structural damage. There is limited information for long-term outcomes regarding the preservation of visual function or optic nerve integrity when directly comparing this combination to other, newer anti-glaucoma agents. Functional outcomes, rather than just the pressure biomarker, are not fully established.

A key research limitation is that much of the evidence relies on IOP as a surrogate outcome—a measurable change in a biological marker (like pressure) used instead of a direct measure of long-term health (like preserving vision). Comparative evidence is lacking for many head-to-head comparisons against some of the current standards of care.

Key Studies & References

1. Health Canada Product Monograph for TIMPILO® (Pilocarpine and Timolol Maleate Ophthalmic Solution)
2. Glaucoma: diagnosis and management (NICE Clinical Guideline [CG85] - Research section reference for dual-action strategy)

Common questions about Фотил (FAQ)

---

Q: What happens if I accidentally put more than one drop in my eye?

Regulatory information suggests that if excess liquid immediately drains from the eye, systemic absorption may be limited. However, because the Timolol component can be absorbed into the bloodstream, an overdose may be associated with systemic symptoms like a slower heart rate or breathing difficulty. Consult a healthcare professional immediately if accidental over-application occurs.

---

Q: Can I take this medicine with my blood pressure pills?

The official product information indicates this medicine may interact with certain types of blood pressure medications. Specifically, using it with oral beta-blockers or certain Calcium Antagonists is generally not recommended. These combinations are listed as potentially increasing the risk of slowed heart rate (bradycardia) or low blood pressure (hypotension). It is important to discuss all current medications, including any blood pressure pills, with a healthcare professional.

---

Q: Will this medicine make my pupils smaller?

Yes. The Pilocarpine component of this combination works to cause pupil constriction (miosis), which is integral to the mechanism for managing eye pressure. Regulatory sources note this effect may be associated with temporary blurred vision and may affect night vision.

---

Q: Can I get this medicine without a prescription?

No. Based on regulatory documents and the drug's classification, Фотил (Pilocarpine/Timolol fixed-dose combination) is officially a prescription-only medicine.

---

Q: Do I need to take out my contact lenses before I use these drops?

Yes. Official administration guidelines state that if you wear soft contact lenses, they must be removed prior to applying the drops. Soft contact lenses should not be reinserted until at least 15 minutes after the application is complete.

---

Q: How long can I keep the eye drops after I open the bottle?

Once the bottle is opened, the solution has a limited 'in-use' stability period. Official product labeling specifies that the solution should be discarded after 28 days from the date of first opening, even if there is still liquid remaining.

---

Q: What are the common side effects that I should look out for?

Official regulatory documents classify common adverse reactions into ocular and systemic effects. Local effects frequently reported include sensations like burning and stinging upon administration, temporary blurred vision, and eye redness (conjunctival injection). Common systemic effects include headache, nausea, and dry mouth.

How to Store and Dispose of Фотил (Pilocarpine/Timolol)

The storage and disposal of Фотил must adhere strictly to regulatory conditions to preserve its stability and safety.

Storage Requirements

The unopened solution requires storage at a controlled temperature, typically either refrigerated (2 C to 8 C) or at controlled room temperature (up to 25 C), as directed by the label. The product must be stored in its original outer carton to protect it from light and must not be frozen.

Once opened, the bottle must be kept tightly closed. The solution has a limited in-use stability and must be discarded after 28 days from the date of first opening, or the period specified in the labeling. All medication must be stored out of the reach and sight of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local regulatory requirements and should not be discarded into household waste or wastewater.